Exenatide

Exenatide is reported to act at the GLP-1 receptor. The source links that receptor activity with glucose-dependent insulin secretion, reduced excess glucagon, delayed gastric emptying, and satiety. It also distinguishes Exenatide from native GLP-1 by noting resistance to DPP-4 degradation: native GLP-1 is described as lasting about two minutes, while Exenatide is reported to circulate with an approximately 2.4-hour half-life. For the once-weekly Bydureon formulation, the source describes slow release from polymer microspheres over days.

The source characterizes Exenatide as an established FDA-approved drug with substantial human clinical experience rather than an experimental compound. It cites peer-reviewed literature, including a 2012 Regulatory Peptides review, for its path from Gila monster venom research to an approved antidiabetic medication. In type 2 diabetes trials, the source reports lower HbA1c and modest weight loss, with nausea identified as the most common side effect and often diminishing over time. It also states that the EXSCEL cardiovascular outcomes trial found once-weekly Exenatide cardiovascularly safe but did not demonstrate a statistically significant reduction in cardiovascular events. Source cautions include rare post-marketing acute pancreatitis reports and lack of recommendation in severe kidney impairment; it also frames Exenatide as an older GLP-1 class option compared with newer agents such as semaglutide and dulaglutide.